CBGD
MCID: CRT033
MIFTS: 47

Corticobasal Degeneration (CBGD) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Corticobasal Degeneration

About this section
Sources:
31ICD10 via Orphanet, 48NIH Rare Diseases, 49NINDS, 54Orphanet, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Corticobasal Degeneration:

Name: Corticobasal Degeneration 48 49 68
Corticobasal Syndrome 48 54
Cortical-Basal Ganglionic Degeneration 48
 
Cortico-Basal Ganglionic Degeneration 48
Cbgd 48

Classifications:



External Ids:

Orphanet54 ORPHA454887
ICD10 via Orphanet31 G31.0

Summaries for Corticobasal Degeneration

About this section
NIH Rare Diseases:48 Corticobasal degeneration is characterized by the break down (degeneration) of parts of the brain, including the cerebral cortex and basal ganglia. the cerebral cortex is responsible for most of the brain's processing of information, and the basal ganglia are deep brain structures that help start and control movement. signs and symptoms of corticobasal degeneration include poor coordination, loss of movement, rigidity, poor balance, unnatural posturing of the muscles, intellectual (cognitive) impairment, speech impairment, muscular jerks, and difficulty swallowing. these symptoms develop and worsen over time. currently the cause of corticobasal degeneration is not known. treatment depends on the symptoms in each person. people with corticobasal degeneration usually do not survive beyond an average of 7 years after symptoms begin. aspiration pneumonia or other complications are usually the cause of death. last updated: 3/13/2017

MalaCards based summary: Corticobasal Degeneration, also known as corticobasal syndrome, is related to progressive supranuclear palsy-corticobasal syndrome and corticobasal degeneration, mapt-related. An important gene associated with Corticobasal Degeneration is MAPT (Microtubule Associated Protein Tau), and among its related pathways are Insulin signalling in human adipocytes (diabetic condition) and EphB-EphrinB Signaling. Affiliated tissues include cortex, brain and eye, and related mouse phenotypes are Decreased viability with paclitaxel and muscle.

NINDS:49 Corticobasal degeneration is a progressive neurological disorder characterized by nerve cell loss and  (shrinkage) of multiple areas of the brain including the cerebral cortex and the basal ganglia. Corticobasal degeneration progresses gradually. Initial symptoms, which typically begin at or around age 60, may first appear on one side of the body (unilateral), but eventually affect both sides as the disease progresses. Symptoms are similar to those found in Parkinson disease, such as poor coordination,  (an absence of movements),  (a resistance to imposed movement), (impaired balance); and limb  (abnormal muscle postures). Other symptoms such as cognitive and visual-spatial impairments, apraxia (loss of the ability to make familiar, purposeful movements), hesitant and halting speech,  (muscular jerks), and  (difficulty swallowing) may also occur. An individual with corticobasal degeneration eventually becomes unable to walk.

Wikipedia:71 Corticobasal degeneration (CBD) or corticobasal ganglionic degeneration (CBGD) is a rare, progressive... more...

Related Diseases for Corticobasal Degeneration

About this section

Diseases in the Corticobasal Degeneration family:

Corticobasal Degeneration, Mapt-Related

Diseases related to Corticobasal Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
idRelated DiseaseScoreTop Affiliating Genes
1progressive supranuclear palsy-corticobasal syndrome12.0
2corticobasal degeneration, mapt-related12.0
3dementia, frontotemporal11.4
4pick disease11.4
5semantic dementia11.2
6leukoencephalopathy, diffuse hereditary, with spheroids10.9
7supranuclear palsy, progressive10.9
8frontotemporal lobar degeneration with ubiquitin-positive inclusions10.9
9apraxia10.4
10dementia10.4
11aphasia10.3
12cerebritis10.3
13neuronitis10.2
14myoclonus10.2
15deafness, autosomal recessive 10110.2CRYAB, MAPT, RPS27A
16severe congenital nemaline myopathy10.1MAPT, RPS27A, TARDBP
17multiple system atrophy10.1
18alzheimer disease10.1
19andersen syndrome10.1MAPT, RPS27A, TARDBP
20hypoproteinemia, hypercatabolic10.1MAPT, RPS27A, TARDBP
21creutzfeldt-jakob disease10.1
22gallbladder adenoma10.0GBA, MAPT, RPS27A
23dystonia10.0
24plekhm1-related autosomal recessive osteopetrosis10.0GBA, MAPT, UCHL1
25acne inversa, familial, 310.0MAPT, RPS27A, TARDBP
26coenzyme q10 deficiency, primary, 110.0GBA, MAPT, RPS27A, TARDBP
27hemochromatosis, type 2a9.9GBA, MAPT, PITX3, RPS27A, UCHL1
28basal ganglia calcification9.9
29lateral sclerosis9.9
30rem sleep behavior disorder9.9
31stiff-person syndrome9.7
32hydrocephalus9.7
33pulmonary fibrosis9.7
34arachnoiditis9.7
35parametritis9.7
36neuroleptic malignant syndrome9.7
37olivopontocerebellar atrophy9.7
38normal pressure hydrocephalus9.7
39antiphospholipid syndrome9.7
40complex regional pain syndrome9.7
41striatonigral degeneration9.7
42arachnoid cysts9.7
43neurosyphilis9.7
44progressive non-fluent aphasia9.7
45ataxia9.7
46cerebral atrophy9.7
47encephalopathy9.7
48spasticity9.7
49posterior cortical atrophy9.7
50craniofacial and skeletal defects7.8CFL1, CRYAB, CSF3, GBA, HSPB2, KIF13B

Graphical network of the top 20 diseases related to Corticobasal Degeneration:



Diseases related to corticobasal degeneration

Symptoms & Phenotypes for Corticobasal Degeneration

About this section

GenomeRNAi Phenotypes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00293-A10.4MTOR, RPS6KB1

MGI Mouse Phenotypes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.8CRYAB, MAPT, MTOR, ROCK1, ROCK2, RPS6KB1
2MP:00107718.7CFL1, CSF3, GBA, MAPT, PITX3, ROCK1
3MP:00030128.3CFL1, KIF13B, MAPT, MTOR, PITX3, SOS1
4MP:00053977.9CSF3, GBA, MAPT, MTOR, PITX3, ROCK1
5MP:00053877.8CSF3, GBA, MAPT, MTOR, PITX3, ROCK1
6MP:00053787.7CFL1, GBA, MAPT, MTOR, PITX3, ROCK1
7MP:00053857.5CFL1, GBA, HSPB2, MAPT, MTOR, PITX3
8MP:00053767.4CFL1, GBA, KIF13B, MAPT, MTOR, PITX3
9MP:00053867.3CFL1, CRYAB, GBA, HSPB2, MAPT, MOBP
10MP:00053847.2CFL1, CRYAB, GBA, HSPB2, MAPT, MTOR
11MP:00036316.9CFL1, GBA, HSPB2, MAPT, MOBP, MTOR

Drugs & Therapeutics for Corticobasal Degeneration

About this section

Drugs for Corticobasal Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1cadexomer iodinePhase 4537
2Pharmaceutical SolutionsPhase 48192
3
IodinePhase 45707553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
4CalamusNutraceuticalPhase 4459
5VitaminsPhase 2, Phase 35282
6UbiquinonePhase 2, Phase 3145
7Trace ElementsPhase 2, Phase 36001
8MicronutrientsPhase 2, Phase 36001
9
Coenzyme Q10experimental, NutraceuticalPhase 2, Phase 3121303-98-05281915
Synonyms:
(all-E)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-Cyclohexadiene-1,4-dione
(all-E)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-Cyclohexadiene-1,4-dione
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-Benzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-Cyclohexadiene-1,4-dione
4-Ethyl-5-fluoropyrimidine
Aqua Q 10L10
Aqua Q10
Bio-Quinon
Bio-Quinone Q10
CoQ10
Coenzyme Q-10
Coenzyme Q10
Ensorb
Kaneka Q10
 
Kudesan
Li-Q-Sorb
Liquid-Q
Neuquinon
Neuquinone
PureSorb Q 40
Q 10AA
Q-Gel
Q-Gel 100
Ubidecarenone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
Ubiquinone-10
Unbiquinone
Unispheres Q 10
10Tranquilizing AgentsPhase 1, Phase 24265
11RadiopharmaceuticalsPhase 2514
12Psychotropic DrugsPhase 1, Phase 26430
13Fluorodeoxyglucose F18Phase 2412
14Lithium carbonatePhase 1, Phase 2240554-13-2
15Antidepressive AgentsPhase 1, Phase 22736
16Antimanic AgentsPhase 1, Phase 2814
17Central Nervous System DepressantsPhase 1, Phase 213403
18taxanePhase 1354
19
Pramipexoleapproved, investigational139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
20
Levodopaapproved40259-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
21
Ropiniroleapproved, investigational7491374-20-8, 91374-21-95095, 497540
Synonyms:
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1)
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]indoline-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
91374-20-8
91374-20-8 (hydrochloride)
91374-21-9
91374-21-9 (Parent)
AB1004799
AC-735
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
AR-1L3132
Adartrel
BIDD:GT0826
BRD-K15933101-003-01-2
C07564
CHEBI:8888
CHEMBL1200411
CHEMBL589
CID5095
CID68727
D00784
D08489
DB00268
EU-0101101
HMS2093K04
I06-0692
I06-0693
JZP-7
L000520
LS-83828
LS-83890
Lopac-R-4152
Lopac0_001101
 
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-04
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NVD-434
R 4152
ReQuip
ReQuip CR
ReQuip LP
ReQuip XL
ReQuip XR
Repreve
Requip (TN)
Ropinirol
Ropinirol [INN-Spanish]
Ropinirole
Ropinirole (INN)
Ropinirole HCl
Ropinirole [INN:BAN]
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor
Ropitor (TN)
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468-A
SPECTRUM1505178
ST51051236
TL8005858
TL8005859
UNII-030PYR8953
UNII-D7ZD41RZI9
ropinirol
22
Carbidopaapproved18428860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
23
Entacaponeapproved, investigational54130929-57-65281081
Synonyms:
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
116314-67-1
130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
AC-393
AC1NQY02
BIDD:GT0026
C071192
C07943
C14H15N3O5
CHEBI:4798
CHEMBL953
CID5281081
COM-998
Comtan
Comtan (TN)
Comtess
D00781
 
DB00494
ENTACAPONE
Entacapona
Entacapona [INN-Spanish]
Entacapone
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
HMS2089O16
KB475572
LS-123327
LS-172316
MolPort-003-847-054
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
Novartis brand of entacapone
OR 611
OR-611
Orion brand of entacapone
UNII-4975G9NM6T
entacapone
24
Amantadineapproved67768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
25Vaccines6611

Interventional clinical trials:

(show all 29)
idNameStatusNCT IDPhase
1DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitationNCT01453127Phase 4
2Effects of Coenzyme Q10 in PSP and CBDCompletedNCT00532571Phase 2, Phase 3
3A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationCompletedNCT00703677Phase 1, Phase 2
4Electrical Polarization of the Brain in Corticobasal SyndromeCompletedNCT00273897Phase 2
5The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission TomographyCompletedNCT01824056Phase 2
6Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyActive, not recruitingNCT01056965Phase 2
7Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy VolunteersCompletedNCT02167594Phase 1
8Safety Study of TPI-287 to Treat CBS and PSPActive, not recruitingNCT02133846Phase 1
9Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and PersonalizedUnknown statusNCT01403519
10The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other DementiasUnknown statusNCT01800214
11Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal DegenerationCompletedNCT01174771
12Study of Tongue PressuresCompletedNCT00013832
13PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UKRecruitingNCT02778607
144-Repeat Tauopathy Neuroimaging Initiative - Cycle 2RecruitingNCT02966145
15Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)RecruitingNCT02365922
16More Than a Movement Disorder: Applying Palliative Care to Parkinson's DiseaseRecruitingNCT03076671
17Parkinson's Disease, Diagnostic Observations (PADDO)RecruitingNCT01249768
18Gait Analysis in Neurological DiseaseRecruitingNCT02994719
19Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.RecruitingNCT02132052
20ADDIA Proof-of-Performance Clinical StudyRecruitingNCT03030586
21Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative DiseaseRecruitingNCT03143374
22The Swedish BioFINDER 2 StudyRecruitingNCT03174938
23Diagnosing Frontotemporal Lobar DegenerationRecruitingNCT02964637
24Genetic Characterization of Movement Disorders and DementiasRecruitingNCT02014246
25Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural NetworksRecruitingNCT03153371
264 Repeat Tauopathy Neuroimaging InitiativeActive, not recruitingNCT01804452
27Study for the Early Diagnosis of Parkinson's DiseaseActive, not recruitingNCT02283073
28Vaccination Uptake (VAX) in PDNot yet recruitingNCT02874274
29SudoScan as a Biomarker of Parkinson's DiseaseNot yet recruitingNCT02767037

Search NIH Clinical Center for Corticobasal Degeneration

Genetic Tests for Corticobasal Degeneration

About this section

Anatomical Context for Corticobasal Degeneration

About this section

MalaCards organs/tissues related to Corticobasal Degeneration:

36
Cortex, Brain, Eye, Thalamus, Spinal cord

Publications for Corticobasal Degeneration

About this section

Articles related to Corticobasal Degeneration:

(show top 50)    (show all 407)
idTitleAuthorsYear
1
Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. (26936765)
2016
2
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. (27526039)
2016
3
Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. (26873956)
2016
4
Progressive supranuclear palsy and corticobasal degeneration: Diagnostic challenges and clinicopathological considerations. (27561438)
2016
5
Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration. (26818518)
2016
6
Incidental corticobasal degeneration. (27461552)
2016
7
Visual signs and symptoms of corticobasal degeneration. (27553583)
2016
8
Tau pathology in aged cynomolgus monkeys is progressive supranuclear palsy/corticobasal degeneration- but not Alzheimer disease-like -Ultrastructural mapping of tau by EDX. (27842611)
2016
9
Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. (27111692)
2016
10
Multimodal evaluation demonstrates in vivo (18)F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. (27815633)
2016
11
Presymptomatic anterior frontal involvement in corticobasal degeneration. (27913406)
2016
12
Diagnoses of corticobasal syndrome and corticobasal degeneration. (26876110)
2016
13
18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. (27645292)
2016
14
Poster 332 Corticobasal Degeneration with Spastic Left Hemiparesis, Dystonic Posturing, and Rigidity: A Case Report. (27673088)
2016
15
Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. (27797812)
2016
16
Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. (27709685)
2016
17
Dopamine transporter imaging as a diagnostic modality for atypical Alzheimer's disease mimicking corticobasal degeneration. (26781839)
2016
18
Therapeutic interventions in parkinsonism: Corticobasal degeneration. (26382843)
2015
19
Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. (25534024)
2015
20
F-18 fluoro-d-glucose positron emission tomography/computed tomography in a patient with corticobasal degeneration. (25829747)
2015
21
Progressive Dopamine Transporter Binding Loss in Autopsy-Confirmed Corticobasal Degeneration. (26485425)
2015
22
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. (26077951)
2015
23
Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients. (25917399)
2015
24
Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. (25708668)
2015
25
Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. (25701010)
2015
26
Corticobasal degeneration initially developing motor versus non-motor symptoms: a comparative clinicopathological study. (25186621)
2014
27
A disease-specific metabolic brain network associated with corticobasal degeneration. (25208922)
2014
28
Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration. (25124031)
2014
29
Suppression of myoclonus in corticobasal degeneration by levetiracetam. (24926409)
2014
30
Neuroleptic Malignant Syndrome in an Elderly Patient With Normal Pressure Hydrocephalus Overlapping Corticobasal Degeneration. (25280791)
2014
31
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. (24521567)
2014
32
Diagnosis and treatment of corticobasal degeneration. (24469408)
2014
33
Argyrophilic grains are reliable disease-specific features of corticobasal degeneration. (24335531)
2014
34
Managing Advanced Progressive Supranuclear Palsy and Corticobasal Degeneration in a Palliative Care Unit: Admission Triggers and Outcomes. (25550443)
2014
35
Corticobasal degeneration. (24963675)
2014
36
Ultrastructural differences in pretangles between Alzheimer disease and corticobasal degeneration revealed by comparative light and electron microscopy. (25497147)
2014
37
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. (25516199)
2014
38
Apraxia in anti-GAD associated stiff person syndrome: Link to corticobasal degeneration? (25100431)
2014
39
Concomitant accumulation of I+-synuclein and TDP-43 in a patient with corticobasal degeneration. (25209854)
2014
40
In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. (24919427)
2014
41
Exome sequencing in familial corticobasal degeneration. (23867865)
2013
42
Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. (24121548)
2013
43
Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. (23720239)
2013
44
Incidental corticobasal degeneration in a 76-year-old woman. (23006474)
2013
45
Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. (23371366)
2013
46
Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration. (23121727)
2013
47
Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration. (23471615)
2013
48
Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy. (23611349)
2013
49
Criteria for the diagnosis of corticobasal degeneration. (23359374)
2013
50
Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. (24114439)
2013

Variations for Corticobasal Degeneration

About this section

Expression for genes affiliated with Corticobasal Degeneration

About this section
Search GEO for disease gene expression data for Corticobasal Degeneration.

Pathways for genes affiliated with Corticobasal Degeneration

About this section

Pathways related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.5MTOR, RPS6KB1
2
Show member pathways
9.5MAPT, ROCK1, ROCK2, SOS1
39.5CFL1, ROCK1, ROCK2
49.3CFL1, MAPT, ROCK1, ROCK2
5
Show member pathways
9.3CFL1, MAPT, ROCK1, ROCK2
69.3MTOR, RPS6KB1, SOS1
7
Show member pathways
9.3MTOR, RPS6KB1, SOS1
89.3MTOR, RPS6KB1, SOS1
9
Show member pathways
9.2CFL1, ROCK1, ROCK2, SOS1
108.9CFL1, ROCK1, ROCK2, RPS6KB1
118.9CFL1, MAPT, MTOR, RPS6KB1
12
Show member pathways
8.7MTOR, ROCK1, ROCK2, RPS6KB1, SOS1
13
Show member pathways
8.7MTOR, ROCK1, ROCK2, RPS6KB1, SOS1
148.7MTOR, ROCK1, ROCK2, RPS6KB1, SOS1
158.6CFL1, MTOR, ROCK1, RPS6KB1, SOS1
168.2HSPB2, MTOR, ROCK1, ROCK2, RPS6KB1, SOS1

GO Terms for genes affiliated with Corticobasal Degeneration

About this section

Cellular components related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:003042410.4CRYAB, KIF13B, MAPT, UCHL1
2myelin sheathGO:00432099.4CRYAB, MOBP, PGAM1, RPS27A, UCHL1
3neuronal cell bodyGO:00430258.7CFL1, MAPT, MTOR, PITX3, SOS1, UCHL1
4cytosolGO:00058297.1CRYAB, HSPB2, KIF13B, MAPT, MTOR, PGAM1
5cytoplasmGO:00057375.7CFL1, CRYAB, HSPB2, KIF13B, MAPT, MOBP

Biological processes related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1axonal transport of mitochondrionGO:001989610.8MAPT, UCHL1
2negative regulation of bicellular tight junction assemblyGO:190334710.6ROCK1, ROCK2
3negative regulation of myosin-light-chain-phosphatase activityGO:003550910.6ROCK1, ROCK2
4regulation of establishment of cell polarityGO:200011410.5ROCK1, ROCK2
5regulation of establishment of endothelial barrierGO:190314010.5ROCK1, ROCK2
6regulation of focal adhesion assemblyGO:005189310.5ROCK1, ROCK2
7regulation of keratinocyte differentiationGO:004561610.5ROCK1, ROCK2
8negative regulation of protein homooligomerizationGO:003246310.5CRYAB, GBA
9regulation of stress fiber assemblyGO:005149210.5ROCK1, ROCK2
10I-kappaB kinase/NF-kappaB signalingGO:000724910.4ROCK1, ROCK2, RPS27A
11negative regulation of cell sizeGO:004579210.3CFL1, MTOR
12regulation of cellular response to heatGO:190003410.3CRYAB, MAPT, MTOR
13regulation of actin cytoskeleton organizationGO:003295610.2MTOR, ROCK1, ROCK2
14regulation of macroautophagyGO:001624110.1GBA, MTOR, UCHL1
15Rho protein signal transductionGO:00072669.8CFL1, ROCK1, ROCK2
16response to amino acidGO:00432009.5CFL1, MTOR, RPS6KB1
17TOR signalingGO:00319299.5MTOR, RPS6KB1
18negative regulation of apoptotic processGO:00430669.2CFL1, CRYAB, PRDX5, RPS27A, RPS6KB1

Molecular functions related to Corticobasal Degeneration according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00055154.9CFL1, CRYAB, GBA, HSPB2, KIF13B, MAPT

Sources for Corticobasal Degeneration

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet